Replies to post #12999 on GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

> a clue to the direction GTC is traveling toward for it's next "partnership" by reading stockdak's message<

Not sure I'm following you here--seems to me that all the
listed applications are on the table for the particular
molecule we are producing, not just cancer. In other words,
we could out-license our onco-IP

http://www.freshpatents.com/Method-of-using-an-anti-cd137-antibody-as-an-agent-for-radioimmunotherapy-or-radioimmunodetection-dt20060824ptan20060188439.php

http://www.freshpatents.com/Anti-cd137-antibody-as-an-agent-in-the-treatment-of-cancer-and-glycosylation-variants-thereof-dt20060817ptan20060182744.php

to a cancer partner but a MAb is a MAb and a partner could just as well in-license IP for other applications if it were necessary.

That CD137 is the most likely candidate for our next deal I think we all agree.